June 11, 2024Dr. Jens Vogel, Senior Vice President and Global Head of Biotechnology at BayerAnnounce resignation from the company where I have worked for four years." He wrote in his LinkedIn post, "After leading and transforming Bayer's global biotech organization for more than four years, it's time for me to move on and seek new opportunities! This is the first break I've taken in my career, where I will first embark on a long journey to Southeast Asia with my family, and then look for a new position.Vogel joined Bayer in March 2020, leading the company’s integrated global biotechnology network, including biologics development, operations and product supply, technology development, as well as strategic functions across the United States and Europe.Function. Prior to this, Vogel worked at Boehringer Ingelheim for nearly 11 years, holding various leadership positions.Although Vogel did not cite broader organizational changes as the reason for his resignation, his departure coincides with Bayer's major restructuring.As early asIn January this year, BayerAnnounced the launch of a comprehensive business reform, itsBelieves that the company is in a "critical situation of survival." In the first three months of 2024, Bayer reduced more than 1,500 positions, of which about2/3It is a management position. As of the end of March, Bayer had less than 98,200 employees, a year-on-year decrease of 3.5%.This business reform can be said to beBayerThe most extensive one since the large-scale restructuring initiated at the end of 2018, the last reorganization of Bayer reduced about 12,000 jobs and sold the group's animal health business.This timeThe layoffs are a result of Bayer's new operating model, known as "Dynamic Shared Ownership," which aims to reduce the hierarchy within the Bayer Group and make it flatter.. CEO of BayerBill Anderson said in separate calls with investors that by the end of 2024, each division of Bayer will begin operating under this model. As a result, Bayer will carry out layoffs worldwide.A spokesperson for Bayer stated, companies typically do not comment on colleagues' decisions to leave. However, Bayer's new head of global biologics manufacturing, Tina Self, confirmed in an interview thatAt BayerDuring the restructuring period, the position of Chief Biotechnology Officer no longer exists.SelfShe took up her new position on June 1st, and her most recent role was at Bayer Berkeley (A 46-acre site located in CaliforniaVice President and Site Manager of Local). At the same time, she also serves as the Site Head of the Berkeley site, making her the first female leader in Bayer's history to hold this position.Tissue reorganization includes regrouping teams into "clusters," steered by Self."Biological Agent Manufacturing Capability Cluster"SheExplained: "We have shifted from a purely technology-based model to a capability-based model.That is now"Everything is organized around capability."Self stated,The design of the new product supply started in December 2023.These clusters are designed to bring together people with similar professional backgrounds.And reduce bureaucracy and hierarchy within the company. This move also aims to enhance the flexibility of the entire organization."Overall, our mission is to provide our patients with excellent, economical, reliable, and high-quality biopharmaceutical production," Self concluded.References:[1]Bayer’s biotech head Jens Vogel says good-bye after 4 years.By Gabrielle Masson.Jun 11, 2024 12:57pm.[2] Bayer's Path of Reform. Pharmaceutical Affairs纵横. 2024-05-31.[3] Bayer's Most Aggressive Streamlining in History: 1,500 Job Cuts, Two-Thirds in Management Positions. MedTrend. 2024-05-15.Scan the WeChat QR code to add.Medicine Space-TimeEditor Please indicate: Name + Research Direction!
